UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 52

Sortiert nach

Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology

Journal of clinical medicine, 2022-01, Vol.11 (3), p.623

2022

Link zum Volltext

Verfügbarkeit prüfen

Steroid treatment of acute graft- versus -host disease grade I: a randomized trial

Haematologica (Roma), 2017-12, Vol.102 (12), p.2125

2017

Link zum Volltext

Verfügbarkeit prüfen

Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives

Journal of clinical medicine, 2022-01, Vol.11 (1), p.253

2022

Link zum Volltext

Verfügbarkeit prüfen

Handheld Ultrasound or Conventional Ultrasound Devices in Patients Undergoing HCT: A Validation Study

Journal of clinical medicine, 2023-01, Vol.12 (2), p.520

2023

Link zum Volltext

Verfügbarkeit prüfen

Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients

Journal of clinical medicine, 2023-01, Vol.12 (2), p.578

2023

Link zum Volltext

Verfügbarkeit prüfen

Transient Leukemoid Reaction from T-Cell Large Granular Lymphocytes Post Autologous Stem Cell Transplant in a Patient Affected by Hodgkin Lymphoma

Hematology reports, 2023-12, Vol.15 (4), p.555-561

2023

Link zum Volltext

Verfügbarkeit prüfen

Preliminary Results of a Combined Score Based on sIL2-Rα and TIM-3 Levels Assayed Early After Hematopoietic Transplantation

Frontiers in immunology, 2020-02, Vol.10, p.3158-3158

2020

Link zum Volltext

Verfügbarkeit prüfen

High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Clinical cancer research, 2017-12, Vol.23 (23), p.7189-7198

2017

Link zum Volltext

Verfügbarkeit prüfen

Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost

Leukemia research reports, 2020-01, Vol.14, p.100227-100227, Article 100227

2020

Link zum Volltext

Verfügbarkeit prüfen

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation

BMC cancer, 2013-02, Vol.13 (1), p.60-60, Article 60

2013

Link zum Volltext

Verfügbarkeit prüfen

Infliximab therapy in hematologic malignancies: handle with care

Haematologica (Roma), 2012-08, Vol.97 (8), p.e26; author reply e27-e26

2012

Link zum Volltext

Verfügbarkeit prüfen

Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib

Clinical management issues, 2015-10, Vol.4 (6S), p.7-11

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of tixagevimab‐cilgavimab versus SARS‐CoV‐2 breakthrough infection in the hematological conditions

Cancer, 2024-01, Vol.130 (1), p.41-50

2024

Link zum Volltext

Verfügbarkeit prüfen

Acute GVHD classification based on the dynamics of GVHD skin involvement from its appearance to the start of systemic treatment

Bone marrow transplantation (Basingstoke), 2024-01, Vol.59 (1), p.17-22

2024

Link zum Volltext

Verfügbarkeit prüfen

Previous therapy with immune checkpoint inhibitor as a cause of hypothyroidism, myositis, and renal insufficiency in a candidate for allogeneic hematopoietic transplantation

Transplant immunology, 2022-12, Vol.75, p.101705, Article 101705

2022

Link zum Volltext

Verfügbarkeit prüfen

Plerixafor on‐demand combined with chemotherapy and granulocyte colony‐stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs

British journal of haematology, 2014-01, Vol.164 (1), p.113-123

2014

Link zum Volltext

Verfügbarkeit prüfen

IBCL-057 Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S446-S447

2023

Link zum Volltext

Verfügbarkeit prüfen

POSTER: IBCL-057 Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S211-S211

2023

Link zum Volltext

Verfügbarkeit prüfen

Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01

Bone marrow transplantation (Basingstoke), 2022-06, Vol.57 (6), p.949-958

2022

Link zum Volltext

Verfügbarkeit prüfen

Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

Blood, 2019-11, Vol.134 (Supplement_1), p.3271-3271

2019

Link zum Volltext

Verfügbarkeit prüfen

Red Cell Distribution Width (RDW) As Prognostic Factor in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Transplantation

Blood, 2017-12, Vol.130, p.5098-5098

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(51)

Publikationsform

Artikel
(48)
Berichte
(4)

Sprache

Englisch
(52)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(26)
Science & Technology
(26)
Hematology
(16)
Humans
(16)
Oncology
(11)
Female
(8)
Male
(8)
Patients
(8)
Stem Cell Transplantation
(7)
Aged
(6)
Immunology
(6)
Antineoplastic Agents - Therapeutic Use
(5)
Hematopoietic Stem Cell Transplantation
(5)
Leukemia
(5)
Transplantation
(5)
Adult
(4)
Bone Marrow
(4)
Chemotherapy
(4)
Cytokines
(4)
General & Internal Medicine
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study

Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology

Steroid treatment of acute graft- versus -host disease grade I: a randomized trial

Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation

Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives

Handheld Ultrasound or Conventional Ultrasound Devices in Patients Undergoing HCT: A Validation Study

Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients

Transient Leukemoid Reaction from T-Cell Large Granular Lymphocytes Post Autologous Stem Cell Transplant in a Patient Affected by Hodgkin Lymphoma

Preliminary Results of a Combined Score Based on sIL2-Rα and TIM-3 Levels Assayed Early After Hematopoietic Transplantation

P1558: PROPHYLAXIS WITH TIXAGEVIMAB‐CILGAVIMAB IN SINGLE‐CENTER EXPERIENCE CAN REDUCE SEVERE COMPLICATIONS RELATED TO SARS‐COV‐2 INFECTION IN HEMATOLOGICAL PATIENTS

High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation

Infliximab therapy in hematologic malignancies: handle with care

Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib

Efficacy and safety of tixagevimab‐cilgavimab versus SARS‐CoV‐2 breakthrough infection in the hematological conditions

Acute GVHD classification based on the dynamics of GVHD skin involvement from its appearance to the start of systemic treatment

Previous therapy with immune checkpoint inhibitor as a cause of hypothyroidism, myositis, and renal insufficiency in a candidate for allogeneic hematopoietic transplantation

Plerixafor on‐demand combined with chemotherapy and granulocyte colony‐stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs

High BCR-ABL/GUS IS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib

IBCL-057 Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis

POSTER: IBCL-057 Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis

Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01

Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

Red Cell Distribution Width (RDW) As Prognostic Factor in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Transplantation

Suchergebnisse filtern